Meta-analysis of efficacy and adverse events of erlotinib-based targeted therapies for advanced/metastatic non-small cell lung cancer

Fei Li, Shu-Hua Zhang and Li-Min Pang _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:86816-86827. https://doi.org/10.18632/oncotarget.19735

Metrics: PDF 1395 views  |   HTML 2270 views  |   ?  


Fei Li1, Shu-Hua Zhang2 and Li-Min Pang3

1Department of Radiotherapy, China-Japan Union Hospital of Jilin University, Changchun 130033, China

2Department of Operation, China-Japan Union Hospital of Jilin University, Changchun 130033, China

3Department of Pediatrics, China-Japan Union Hospital of Jilin University, Changchun 130033, China

Correspondence to:

Li-Min Pang, email: [email protected]

Keywords: advanced/metastatic non-small-cell lung cancer, targeted therapy, efficacy, adverse events, randomized controlled trials

Received: March 29, 2017     Accepted: July 19, 2017     Published: July 31, 2017


A network meta-analysis evaluating efficacy and adverse events of eight erlotinib-based therapies (erlotinib+placebo, erlotinib+tivantinib, erlotinib+celecoxib, erlotinib+onartuzumab, erlotinib+sunitinib, erlotinib+entinostat, erlotinib+sorafenib, and erlotinib+bevacizumab) for advanced/metastatic non-small-cell lung cancer (NSCLC) was performed. PubMed and Cochrane Library were reviewed, and ten randomized controlled trials were identified in which patients receiving at least one erlotinib-based therapy. Efficacy outcomes, including progression-free survival (PFS), overall survival (OS), overall response rate (ORR), disease control rate (DCR), and adverse outcomes were evaluated. Patients treated with erlotinib+tivantinib, or erlotinib+celecoxib had longer PFS than patients on erlotinib+placebo; patients on erlotinib+tivantinib had longer OS compared to erlotinib+placebo. For PFS, erlotinib+celecoxib had the highest value of surface under the cumulative ranking curve (SUCRA). For OS, erlotinib+tivantinib had the highest SUCRA. For ORR, erlotinib+bevacizumab had the highest SUCRA, while erlotinib+entinostat ranked the lowest. For DCR, erlotinib+sorafenib had the highest SUCRA. Erlotinib+onartuzumab had the highest SUCRA for diarrhea, nausea, vomiting, decreased appetite, and dyspnea. Erlotinib+sunitinib had the lowest SUCRA for diarrhea, nausea, vomiting, and decreased appetite. Erlotinib + entinostat had the lowest SUCRA for fatigue, asthenia, and dyspnea. Our study suggests erlotinib+tivantinib and erlotinib+celecoxib regimens have the best long-term efficacy, while erlotinib+sunitinib and erlotinib+entinostat have the fewest adverse effects in patients with advanced/metastatic NSCLC.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19735